课题基金 / 基金详情

in vivo characterization of D2/D3 agonists & antagonists

in vivo characterization of D2/D3 agonists & antagonists
D2/D3 激动剂的体内表征
批准号:
6999043
负责人:
Gregory Thomas Collins
金额:
$3.36万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-05 至 2008-09-04

项目摘要

项目成果

Gregory Thomas Collins的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The dopamine D2 and D3 receptors are differentially expressed at high levels within the mesolimbic dopaminergic system and the nucleus accumbens, areas known to be important in the regulation of the reinforcing properties of drugs of abuse. It is hypothesized that the dopamine D2 and D3 receptors are differentially involved in reward and reinforcement, and that utilization of selective D2 and D3 agonists and antagonists will allow for a more accurate assessment of the in vivo roles of the D2 and D3 receptors. Assignment of roles for D2 and D3 has been complicated by the fact that there are currently no purely D2 or D3 selective agonists or antagonists, rather existing compounds have varying degrees of selectivity for D2 and D3. The specific aims to be tested are: (1) in vivo characterization of existing and novel dopaminergic agonist and antagonist with regard to their selectivity for, and activities at the D2 and D3 receptors in rhesus monkeys and rats, (2) investigation of the reinforcing properties of D2 and D3 acting agonists and antagonists, and (3) evaluation of D2 and D3 agonists and antagonists with regard to their ability to modulate reinforcement maintained by psychostimulants such as cocaine. Taken together, the results of these experiments will allow for a better understanding of the specific roles of the D2 and D3 receptors in the reward and reinforcement pathways of the brain as well as provide valuable information towards the development of novel compounds as well as therapeutics aimed at drug abuse and addiction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical Psychopharmacology of Substance Abuse
Preclinical Psychopharmacology of Substance Abuse
Preclinical Psychopharmacology of Substance Abuse
Repurposing drugs in mixtures to treat drug abuse
海外基金